Results 231 to 240 of about 28,869 (265)

Not all is perfect with Tenofovir alafenamide

HIV Medicine, 2019
S Noe, C Jonsson‐Oldenbuettel, H Jaeger   +2 more
openaire   +2 more sources

Antineoplastics/tenofovir-alafenamide

Reactions Weekly, 2022
openaire   +1 more source

Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis

Hepatology International
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim   +4 more
semanticscholar   +1 more source

Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate

Clinical Gastroenterology and Hepatology, 2022
Kwan Soo Byun, Jonggi Choi, Han Chu Lee
exaly  

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet, The, 2020
Kenneth Mayer, Jean-Michel Molina, Peter L Anderson   +2 more
exaly  

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B

Liver International, 2022
Jihye Lim, Won-Mook Choi, Ju Hyun Shim
exaly  

Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B

Liver International, 2022
Chan-Young Jung, Hyung Woo Kim, Sang Hoon Ahn   +2 more
exaly  

Tenofovir alafenamide

Reactions Weekly, 2019
openaire   +1 more source

Tenofovir-alafenamide withdrawal

Reactions Weekly, 2022
openaire   +1 more source

Entecavir/tenofovir-alafenamide

Reactions Weekly, 2023
openaire   +1 more source